National Drug Control Policy Office 2020 – Federal Register Recent Federal Regulation Documents
Results 1 - 6 of 6
Freedom of Information Act
The Office of National Drug Control Policy (ONDCP) is updating its Freedom of Information Act (FOIA) implementing regulation to comport with the FOIA Improvement Act of 2016 and best practices. The final rule describes how to make a FOIA request with ONDCP and how the Office of General Counsel, which includes the ONDCP officials authorized to evaluate FOIA requests, processes requests for records. The final rule also states ONDCP's Privacy Act Policies and Procedures. The final rule describes how individuals can learn if an ONDCP system of records contains information about them and, if so, how to access or amend a record.
Appointment of Members of Senior Executive Service Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Martha Gagn[eacute] (as Chair), Mr. Kemp Chester, Mr. Eric Talbot, and Dr. Terry Zobeck.
Designation of Three Areas as High Intensity Drug Trafficking Areas
The Director of the Office of National Drug Control Policy designated 3 additional areas as High Intensity Drug Trafficking Areas (HIDTA).
Designation of Twelve Areas as High Intensity Drug Trafficking Areas
The Director of the Office of National Drug Control Policy designated 12 additional areas as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706(b)(1). The new areas are (1) Davidson County in Tennessee as part of the Appalachia HIDTA; (2) Chatham County in Georgia as part of the Atlanta/Carolinas HIDTA; (3) Manatee and Leon Counties in Florida as part of the Central Florida and North Florida HIDTAs, respectively; (4) Lake County in Illinois as part of the Chicago HIDTA; (5) Chambers County in Texas as part of the Houston HIDTA; (6) Vanderburgh County in Indiana as part of the Indiana HIDTA; (7) Eau Claire County in Wisconsin as part of the North Central HIDTA; (8) Grant County in Washington as part of the Northwest HIDTA; (9) Westmoreland County in Pennsylvania as part of the Ohio HIDTA; (10) Kootenai County in Idaho as part of the Oregon/Idaho HIDTA; and (11) Allegany County in Maryland as part of the Washington/Baltimore HIDTA. The Director of ONDCP also removed one area as a HIDTA pursuant to 21 U.S.C. 1706(c), effective May 27, 2020. The area removed from HIDTA designation is Barrow County in Georgia as part of the Atlanta/ Carolinas HIDTA. The Executive Board of Atlanta/Carolinas HIDTA requested removal of Barrow County from designation after assessing the threat and determining that it no longer met the statutory criteria necessary for designation as a HIDTA county. ONDCP evaluated and accepted the request.
Freedom of Information Act
The Office of National Drug Control Policy (ONDCP) is updating its Freedom of Information Act (FOIA) implementing regulation to comport with the FOIA Improvement Act of 2016 and best practices. The proposed rule describes how to make a FOIA request with ONDCP and how the Office of General Counsel, which includes the ONDCP officials authorized to evaluate FOIA requests, processes requests for records. The proposed rule also states ONDCP's Privacy Act Policies and Procedures. The proposed rule describes how individuals can find out if an ONDCP system of records contains information about them and, if so, how to access or amend a record. ONDCP seeks comments on all aspects of the proposed rule and will thoroughly consider all comments that are submitted on time.
Criteria for Designation of Emerging Drug Threats in the United States
The Office of National Drug Control Policy is announcing this Advance Notice of Proposed Rulemaking (ANPRM) and requests information relevant to criteria for designating and terminating the designation of emerging drug threats in the United States pursuant to the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). This ANPRM briefly summarizes the White House Office of National Drug Control Policy's (ONDCP) ongoing work in this area and describes the criteria that ONDCP is considering to monitor and identify emerging drug threats. The ANPRM invites interested parties to submit comments, data, and other pertinent information concerning ONDCP's development of proposed criteria for designating emerging drug threats and terminating such designations.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
